What To Expect From Scholastic’s (SCHL) Q2 Earnings

Scholastic (NASDAQ: SCHL) is set to report Q2 earnings Thursday. The company previously missed revenue expectations with $329.1M revenue, down 1.9% YoY, though it beat EPS and missed EBITDA. For this quarter, analysts expect revenue up 1.7% YoY. SCHL has an average analyst price target of $42 versus $46.82.

Original reporting
Published Jul 22, 2026, 3:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 3:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What To Expect From Scholastic’s (SCHL) Q2 Earnings — source image
Decision brief

The 30-second read

$SCHLNeutralLow
01

Why it matters

Traders can use the provided consensus framing (1.7% YoY revenue growth expectation) and the prior-quarter mix (EPS beat, EBITDA miss) to calibrate expectations for the upcoming print, but the article does not introduce new company-specific disclosures.

02

Market read

The main tradable element is timing (earnings this Thursday) and the consensus setup, not a fresh disclosure.

03

What to watch

The article highlights prior-quarter EBITDA underperformance but does not discuss guidance, margin drivers, or segment trends that typically determine post-earnings repricing.

Relevance 4/10Novelty 3/10Timing: Ahead of Scholastic’s Q2 earnings this Thursday afternoon.

Background

Scholastic missed revenue expectations last quarter (revenue $329.1M, down 1.9% YoY) while beating EPS, and it has missed revenue estimates multiple times over the last two years.

Company-level read

Ticker impact

$SCHLNeutralMedium confidence
Context

Scholastic is set to report Q2 results this Thursday, with consensus expecting 1.7% revenue growth and the stock up 10.1% pre-earnings.

Expected impact

Likely modest volatility around the release, driven by whether revenue and EBITDA trends align with the preview’s expectations.

Evidence & confidence

The article provides expectations (revenue growth, reconfirmed estimates) and prior-quarter context (revenue miss, EPS beat, EBITDA miss) but no new guidance, filings, or datapoint.

Market effects

Limited read-across from consumer discretionary peers (AMC, Delta) since the article does not provide new sector data or Scholastic-specific operational updates.

No specific regional linkage beyond US-listed consumer discretionary earnings season context.

Minimal, as the piece is focused on a single US company’s upcoming earnings.

Counterpoint

A pre-earnings preview can understate downside risk if the market is already positioned for a revenue beat but EBITDA or margins remain pressured.

Key entities

  • Scholastic

    Educational publishing and media company reporting Q2 results this Thursday afternoon.

  • AMC Entertainment

    Peer cited for Q2 revenue growth and post-results stock reaction.

  • Delta Air Lines

    Peer cited for Q2 revenue growth and post-results stock reaction.

Related articles

$SCHLMed

Scholastic Corporation Q4 2026 Earnings Call Summary

Scholastic (Scholastic Corporation) reported a 32% rise in adjusted operating income attributed to a multiyear efficiency and integrated publishing and school growth transformation. Management said Book Fairs growth was driven by higher fair counts and digital tools. Fiscal 2027 guidance calls for 2% to 4% revenue growth and higher adjusted EBITDA, with capital returns supported by sale-leasebacks and leverage targets of 2x to 2.5x.

$SCHLMed

SCHOLASTIC CORP (SCHL): Results of Operations and Financial Condition

SCHOLASTIC CORP (SCHL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fy26q4pressrelease.htm EX-99.1 Document Scholastic Reports Fourth Quarter and Fiscal 2026 Results Fiscal 2026 Operating Income of $15.2 Million; Adjusted EBITDA of $151.5 Million, Up 4%, in Line With Guidance Returned Over $285 Million to Shareholders During Fiscal Year

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.